Table 2. Summary case report 1 and 2.

Case	Age/ Gender	CAC	Organ involvement/ Presentation	Genetic	Eculizumab duration/doses	Creatinine (µmol/L) at the end of eculizumab	Creatinine (µmol/L) at last follow-up	Relapse	Follow-up (months)
1	52 y/F	Docetaxel Doxorubicin	Kidney/acute CNS/acute Lungs/acute	CFH polymorphism synonymous variant c.1419 G>A, p.Ala4773 Ala	5 weeks/6	120	83	No	47
2	57 y/F	Gemcitabine	Kidney/chronic Severe hypertension	CFH polymorphism Synonymous variant c.1419 G>A p.Ala473 Ala	10 weeks/8	154	140	No	15

CAC = complement activating condition; CNS = central nervous system; CFH = complement factor H.